Hyper-CVAD

DRUG5 trials

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University, M.D. Anderson Cancer Center, The Affiliated People's Hospital of Ningbo University, The First Affiliated Hospital of Soochow University

Conditions

Acute Lymphoblastic LeukemiaAdult T-cell Leukemia/LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeB-cell Acute Lymphocytic LeukemiaBi-Phenotypic LeukemiaBurkitt LymphomaHematopoietic Stem Cell MobilizationLymphoblastic Lymphoma

Early Phase 1

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

CompletedNCT01184885

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAcute Lymphoblastic Leukemia, Adult T-cell Leukemia/Lymphoma, Burkitt Lymphoma +3

Start: 2010-07-31End: 2013-04-30Updated: 2025-05-04

Phase 1

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

RecruitingNCT06287229

M.D. Anderson Cancer CenterB-cell Acute Lymphocytic Leukemia, Relapsed/Refractory

Start: 2024-07-11End: 2030-12-31Target: 40Updated: 2026-04-24

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

RecruitingNCT06466395

M.D. Anderson Cancer CenterBi-Phenotypic Leukemia, Refractory Acute Leukemia, Relapsed Acute Leukemia +1

Start: 2025-02-18End: 2031-12-31Target: 22Updated: 2026-03-09

Phase 2

Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

RecruitingNCT07564453

The First Affiliated Hospital of Soochow UniversityB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Start: 2025-04-01End: 2028-06-30Target: 101Updated: 2026-05-04

Phase 3

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

RecruitingNCT06520163

The Affiliated People's Hospital of Ningbo UniversityHematopoietic Stem Cell Mobilization, Non-Hodgkin's Lymphoma

Start: 2024-08-01End: 2026-08-31Target: 99Updated: 2025-12-04

Related Papers

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Blood2025-11-03

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

Blood2025-11-03